Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Lysosomal alpha-mannosidase and alpha-mannosidosis.

Author information

Affiliations

  • 1. Department of Medicine, Section of Neurology, University of Perugia, Sant'Andrea delle Fratte, 06132 Perugia, Italy.
      Authors
    • Paciotti S 1
    • Tasegian A 1
    (2 authors)
  • 2. Department of Pharmaceutical Sciences, University of Perugia, Via Fabretti 48, 06123 Perugia, Italy.
      Authors
    • Codini M 2
    • Ceccarini MR 2
    • Cataldi S 2
    (3 authors)
  • 3. Department of Experimental Medicine, University of Perugia, Polo Unico Sant'Andrea delle Fratte, Piazzale Gambuli, 06132 Perugia, Italy.
      Authors
    • Arcuri C 3
    (1 author)
  • 4. Department of Chemistry, Biology and Biotechnology, Via Elce di sotto, 06123, Perugia, Italy.
      Authors
    • Fioretti B 4
    (1 author)
  • 5. Laboratory of Nuclear Lipid BioPathology, CRABiON, Perugia 06122, Italy.
      Authors
    • Albi E 5
    (1 author)
    • Show all (6)

ORCIDs linked to this article

Frontiers in Bioscience (Landmark Edition), 01 Jan 2017, 22(1):157-167
https://doi.org/10.2741/4478 PMID: 27814608 

Review

Abstract 

Lysosomal alpha-mannosidase with acidic pH optimum is ubiquitous in human tissues where is expressed in two major forms, A and B that are the product of a single gene located on chromosome 19. Mutations in the gene encoding for alpha-mannosidase cause alpha- mannosidosis, an autosomal recessive disease, resulting in the accumulation of unprocessed mannose containing oligosaccharide material. This rare disease has an estimated incidence of 1/500.0.00 live births and clinically is divided into three subgroups. Today the most promising therapy for this disease is the enzyme replacement therapy. To develop this strategy a mouse model for alpha-mannosidosis has been generated and a recombinant human alpha-mannosidase has been produced from Chinese-hamster ovary cells. Interestingly it has been shown that the recombinant enzyme, used in high dose, can cross the blood brain barrier. This recombinant enzyme has been tested in the first randomized study investigating the efficacy of enzyme replacement therapy in patients with alpha-mannosidosis. This review contains the scientific progresses on lysosomal alpha-mannosidase from the cloning to the beginning of the therapy.

Full text links 

Read article at publisher's site: https://doi.org/10.2741/4478

Citations & impact 

Impact metrics

9
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/31330031
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/31330031

Article citations

Go to all (9) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.